SEC Form 4 · accession 0001209191-17-046031
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul M Silva
Officer — SVP & Corp Controller
Period of report
Jul 19, 2017
Accepted (ET)
Jul 21, 2017 · 8:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 19, 2017 | M | 6,445 | $77.31 | A | 26,516 | D | |
| Common Stock | Jul 19, 2017 | M | 4,500 | $48.74 | A | 31,016 | D | |
| Common Stock | Jul 19, 2017 | M | 8,438 | $45.11 | A | 39,454 | D | |
| Common Stock | Jul 19, 2017 | M | 3,437 | $83.36 | A | 42,891 | D | |
| Common Stock | Jul 19, 2017 | M | 3,437 | $96.87 | A | 46,328 | D | |
| Common Stock | Jul 19, 2017 | M | 3,867 | $109.14 | A | 50,195 | D | |
| Common Stock | Jul 19, 2017 | M | 6,445 | $91.05 | A | 56,640 | D | |
| Common Stock | Jul 19, 2017 | M | 3,437 | $90.29 | A | 60,077 | D | |
| Common Stock | Jul 19, 2017 | S | 40,006 | $161.00 | D | 20,071 | D | |
| Common Stock | Jul 21, 2017 | S | 2,937 | $161.91 | D | 17,134 | D | |
| Common Stock | Jul 21, 2017 | S | 500 | $161.92 | D | 16,634 | D | |
| Common Stock | holding | — | — | — | 169 | I | 401k |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $77.31 | Jul 19, 2017 | M | 6,445 | D | — | Feb 4, 2024 | Common Stock | 6,445 | 3,867 | D |
| Stock Option (Right to Buy)F3 | $48.74 | Jul 19, 2017 | M | 4,500 | D | — | Jul 24, 2022 | Common Stock | 4,500 | 0 | D |
| Stock Option (Right to Buy)F3 | $45.11 | Jul 19, 2017 | M | 8,438 | D | — | Feb 4, 2023 | Common Stock | 8,438 | 0 | D |
| Stock Option (Right to Buy)F4 | $83.36 | Jul 19, 2017 | M | 3,437 | D | — | Jul 29, 2023 | Common Stock | 3,437 | 860 | D |
| Stock Option (Right to Buy)F5 | $96.87 | Jul 19, 2017 | M | 3,437 | D | — | Jul 14, 2024 | Common Stock | 3,437 | 10,313 | D |
| Stock Option (Right to Buy)F6 | $109.14 | Jul 19, 2017 | M | 3,867 | D | — | Feb 2, 2025 | Common Stock | 3,867 | 16,758 | D |
| Stock Option (Right to Buy)F7 | $91.05 | Jul 19, 2017 | M | 6,445 | D | — | Feb 1, 2026 | Common Stock | 6,445 | 14,180 | D |
| Stock Option (Right to Buy)F8 | $90.29 | Jul 19, 2017 | M | 3,437 | D | — | Jul 11, 2026 | Common Stock | 3,437 | 10,313 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Silva's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 2/5/2014.
- F3Fully vested.
- F4The option vests in 16 quarterly installments from 7/30/2013.
- F5The option vests in 16 quarterly installments from 7/15/2014.
- F6The option vests in 16 quarterly installments from 2/3/2015.
- F7The option vests in 16 quarterly installments from 2/2/2016.
- F8The option vests in 16 quarterly installments from 7/12/2016.